Etoricoxib + Betamethasone fixed dose

Phase 3

Laboratorios Farmaceuticos Rovi, S.A./ADR (LRVIY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '26

LRVIYPhase 3

Etoricoxib + Betamethasone fixed dose Phase 3 Est. Readout

Etoricoxib + Betamethasone fixed dose• Gout Arthritis72

Q4 2026~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Gout Arthritis

View Full Landscape

Drug Information

Target Indication

Gout Arthritis

Clinical Trial

NCT06863701

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

LRVIY

Laboratorios Farmaceuticos Rovi, S.A./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

Depigoid Parietaria judaica 1000DPP/mlPhase 3

Allergic Rhinoconjunctivitis

Glucosamine and chondroitin sulfate combination (Eurofarma)Phase 3

Osteoarthritis of Knee

Minoxidil Topical FoamPhase 3

Alopecia

Study group - quadrivalent recombinant hemagglutinin influenza vaccinePhase 3

Influenza, Human

Chlorthalidone 25 mg + amiloride hydrochloride 5 mgPhase 3

Arterial Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts